Medication adherence in patients in treatment for rheumatoid arthritis and systemic lupus erythematosus in a university hospital in Brazil

Patient Preference and Adherence

Volumn 10, Issue , 2016, Pages 863-870

  Prudente, Luciana Resende ^a   Diniz, Juliana de Souza ^a   Ferreira, Tatyana Xavier Almeida Matteucci ^a   Lima, Dione Marçal ^a   Silva, Nílzio Antônio ^a   Saraiva, Guylherme ^a   Silveira, Erika Aparecida ^a   Dewulf, Nathalie de Lourdes Souza ^a   Amaral, Rita Goreti ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Compliance; Phamacotherapy; Rheumatic diseases

Indexed keywords

ADULT; ARTICLE; BRAZIL; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEALTH SERVICE; HUMAN; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORISKY SCALE QUESTIONNAIRE; OUTPATIENT; PHARMACY; PREVALENCE; QUANTITATIVE STUDY; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; STRUCTURED QUESTIONNAIRE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; UNIVERSITY HOSPITAL;

EID: 84969784585     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S79451     Document Type: Article

References (28)

1. Goeldner I, Skare TL, Reason ITM, Utiyama RR. Rheumatoid arthritis: a current view. J Bras Patol Med Lab. 2011;47(5):495-503.
2. Al Dhanhani AM, Gignac MAM, Jiandong S, Fortin PR. Work disability in systemic lupus erythematosus. Arthritis Rheum. 2009;61(3):378-385.
3. Huscher D, Merkesdal S, Thiele K, et al; German Collaborative Arthritis Centres. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006;65(9):1175-1183.
4. Zhu TY, Tam LS, Li EK. Cost-of-illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2011;63(5):751-760.
5. Wille E, Scholze J, Alegria E, et al. Uhl-Hochgraeber modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy. Eur J Health Econ. 2011;12:205-218.
6. Spies CM, Bijlsma JWJ, Buttgereit F. Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol. 2010;10(3):302-307.
7. Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. 2011;13(10):1375-1385.
8. Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15(14):1-278.
9. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-632.
10. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analyses. Med Care. 2002;40(9):794-811.
11. World Health Organization (WHO). Adherence to Long-Term Therapies: Evidence for Action. 2003. Available from: whqlibdoc.who.int/publications/2003/9241545992.pdf
12. Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve medication adherence. Eur Heart J. 2011;32(3):264-268.
13. Elliott RA. Poor adherence to medication in adults with rheumatoid arthritis. Dis Manag Health Outcomes. 2008;16(1):13-29.
14. Oliveira-Santos M, Verani J, Klumb E, Albuquerque E. Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus. 2011;20(3):320-329.
15. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
16. Melchiors AC, Correr CJ, Fernández-Llimos F. Translation and validation into Portuguese language of the medication regimen complexity index. Arq Bras Cardiol. 2007;89(4):210-218.
17. Tan X, Patel I, Chang J. Review of the four item Morisky medication adherence scale (MMAS-4) and eight item Morisky medication adherence scale (MMAS-8). Inov Pharm. 2014;5(3):8. [article 165].
18. Trauthman SC, Biudes MF, Mello AF, Rosa FS, Peters CA, Galato D. Methods for evaluation of therapeutic medication adherence adopted in Brazil. Infarma Cienc Farm. 2014;26(1):11-26.
19. Dewulf NLS, Monteiro RA, Passos ADC, Vieira EM, Troncon LEA. Compliance to drug therapy in inflammatory bowel diseases outpatients from an university hospital. Arq Gastroenterol. 2007;44(3):289-296.
20. Harrold LR, Andrade SE. Medication adherence of patient with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum. 2009;38(5):396-402.
21. de Achaval S, Suarez-Almazor ME. Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumtol. 2010;5(3):313-326.
22. Dosse C, Cesarino CB, Martin JFV, Castedo MCA. Factors associated with patients’ noncompliance with hypertension treatment. Rev Lat Am Enfermagem. 2009;17(2):201-206.
23. Bloch KV, Melo NA, Nogueira AR. Prevalence of anti-hypertensive treatment adherence in patients with resistant hypertension and validation of three indirect methods for assessing treatment adherence. Cad Saude Publica. 2008;24(12):2979-2984.
24. Sokol MC, Mcguigan KA, Verbrugge RR, Epstein RS. Impact of medication on adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
25. Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M, et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2008;27(7):883-889.
26. Goldring AB, Taylor SE, Kemeny ME, Anton PA. Impact of health beliefs, quality of life and the physician-patient relationship on the treatment intentions of inflammatory bowel disease patients. Health Psychol. 2002;21(3):219-238.
27. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patients adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331-342.
28. Maneeton B, Maneeton N, Louthrenoo W. Prevalence and predictors of depression in patients with systemic lúpus erythematosus: a cross-sectional study. Neuropsychiatr Dis Treat. 2013;9:799-804.